Source: Gannon et al.

Report
Carbon NanotubeBased Cancer
Therapeutics
Medical
Nanotechnologies
Incorporated
Rob Burgess, Ph.D.
Founder and President
www.nanomedinc.com
Zyvex Corporation and Zyvex Performance
Materials – Carbon Nanotube
MedNanoTech
Functionalization
2
Zyvex Performance Materials’
Technical Approach
MedNanoTech
Zyvex NanoSolve® Enhanced Composites
•
•
•
•
•
•
Sizing agent or tailored coupling agent
Exfoliation of CNT
Uniform dispersion
Adhesion to polymer
Not a surfactant
Other advanced capabilities
— Process knowledge
— Custom formulations
Two distinct functions:
•
Non-damaging binding to the CNT
•
Kentera™ Technology
3
Customizable adhesion to host material
(example: polymer such as epoxy)
Enables CNTs in Composites
Kentera-Conjugated Carbon
Nanotubes are Soluble in Water
•Customizable side chains confer solubility
4
MedNanoTech
RF-mediated CNT Thermal Conductivity
MedNanoTech
RF field
RF
Transmitter
RF
Receiver
Target
area
Source: Adapted from US
Patent Application
2005/0251234 A1
Inventors: Kanzius et al.
CNT-introduced
regions
Source:
Gannon et
al.
5
CNT Functionalization
MedNanoTech
Carbon nanotubes can be functionalized
with antibodies and polar lipids.
AFM
TEM
Source:
Chakravarty
et al.
AFM
Source: Marches
et al.
6
CNT Intracellular Delivery
MedNanoTech
Intracellular Accumulation of
PEDOT/PSS-Conjugated Carbon
Nanotubes
HEK293 Cells
72 hours post-treatment
7
Source: Draper et al.
Carbon nanotube properties make them a
unique platform for therapeutic
MedNanoTech
applications.
• Organized Structure
• Mechanism of Action
Known
• RF and Near IR
Sensitive
• Electrically and
Thermally Conductive
• Can be Functionalized
with a Variety of
Molecules
• Can Penetrate Cells
8
CNT Cytotoxicity
MedNanoTech
Kentera and Kentera-conjugated carbon
nanotubes are minimally cytotoxic.
9
Source: Draper et al.
Antibody/CNT Cell Surface
Binding and Cytotoxicity
Antibody/lipid-coated
carbon nanotubes are
noncytotoxic and bind
specifically to cancer cells.
Daudi Cells
Source:
Chakravarty
et al.
Source:
Marches et al.
10
MedNanoTech
Cell Surface Binding
MedNanoTech
Antibody-coated carbon nanotubes bind
specifically to cancer cells.
11
Source:
Chakravarty
et al.
CNT- Based Cancer Therapeutics
MedNanoTech
Cancer cells are
effectively ablated
by carbon
nanotubes in the
presence of NIR
light.
12
Source:
Chakravarty
et al.
CNT- Based Cancer Therapeutics
MedNanoTech
Panc-1 cells containing Kentera-conjugated
carbon nanotubes are efficiently ablated upon
RF exposure.
No SWNTs
11% PI Stained
13
SWNTs
99.7% PI Stained
Source: Gannon et al.
Intratumoral CNT/Kentera injections
demonstrate RF-mediated cellular
MedNanoTech
ablation.
Kentera/SWNTs
Kentera
H&E
TUNEL
14
Source:
Gannon et al.
Proposed Product Pipeline –
Moving Towards Targeting CNTs
Monoclonal
Antibody
Cell Surface Breast, Colorectal,
Head and Neck
MedNanoTech
Her2, Erbitux
Small Molecule Cell
Surface,
Intracellular
Lung
Tarceva, Iressa
Aptamer
Cell
Surface,
Intracellular
Renal, Lung
AS1411 (in dev.)
Peptide
Cell
Surface,
Intracellular
Breast, Thyroid
RGD (in dev.)
Targeting
Agent
Mode of
Action
Cancer
Application
Known
Example(s)
15
Criteria for Success: Targeted
CNT Cancer Therapeutics
MedNanoTech
 Functionality
Dispersion - Effective aqueous dispersion must be demonstrated.
Efficacy – CNT’s must aggressively ablate targeted tissue.
• Toxicity – CNT’s and polymer functionalization must be demonstrated
as nontoxic.
• Specificity – CNT’s must be successfully targeted to tumorigenic
tissue and away from healthy tissue.
16
Acknowledgments
MedNanoTech
Zyvex Corporation
Jim Von Ehr
Gareth Hughes, Ph.D.
Tanja Kmecko
UT-Dallas
Rocky Draper, Ph.D.
Paul Pantano, Ph.D.
Inga Musselman, Ph.D.
UT-SW Medical Center
Ellen Vitetta, Ph.D.
Radu Marches, Ph.D.
Pavitra Chakravarty, Ph.D.
UT-MD Anderson
Cancer Center
Steve Curley, M.D.
Nanoco, LLC
Peter Wilk, M.D.
17
For Further Information
MedNanoTech
Rob Burgess, Ph.D.
President
Medical Nanotechnologies, Inc.
Email: [email protected]
Phone: 214-440-2311
www.nanomedinc.com
18

similar documents